Dr. Mark Hamilton
Director of the University of Calgary Adult Hydrocephalus Program
Professor of Neurosurgery, Departments of Clinical Neurosciences, Surgery & Pediatrics
Former Division Head of Pediatric Neurosurgery, Alberta Children’s Hospital
Board of Directors, Hydrocephalus Association
Dr. Mark Hamilton, MDCM, FRCSC, FAANS, is from the University of Calgary, Department of Clinical Neurosciences, Division of Neurosurgery. Dr. Hamilton did his Bachelor of Science degree (with distinction) at the University of Toronto and then graduated from McGill University Medical School in 1983. He did his Neurosurgery Residency at the University of Calgary and received his FRCSC in 1991. He did Fellowship training in the cerebrovascular, skull base, and pediatric Neurosurgery at the Barrow Neurological Institute in Phoenix, Arizona, and joined the University of Calgary Department of Clinical Neurosciences in 1994, where he is currently a Professor of Neurosurgery with additional appointments in the Department of Surgery and the Department of Pediatrics. He was the Chief of the Division of Pediatric Neurosurgery from 2002-2011. He is head of the University of Calgary Adult Hydrocephalus Program, which he established with the University of Calgary Adult Hydrocephalus Clinic in 2008. Dr. Hamilton is the chair of the Adult Hydrocephalus Clinical Research Network (AHCRN), which has eight clinical sites in three countries, Past-President of the Hydrocephalus Society (International Society for Hydrocephalus and Cerebrospinal Fluid Disorders (ISHCSF)), a member of the Board of Directors of the Hydrocephalus Association (HA), Vice-Chair of the Medical Advisory Board (MAB) of HA, a member of the Board of Directors of Hydrocephalus Canada, and a member of the Editorial Boards of the Journal of Neurosurgery, Neurosurgery, The Canadian Journal of Neurological Sciences, and Fluids and Barriers of the CNS. His current main clinical and research interests are diagnosing and managing hydrocephalus in adults. The AHCRN has undertaken a 2021 NIH-funded, blinded, randomized clinical trial to assess shunt treatment’s efficacy in patients with idiopathic Normal Pressure Hydrocephalus (iNPH) diagnosis.